Catalog Number 955540 |
Device Problem
Adverse Event Without Identified Device or Use Problem (2993)
|
Patient Problems
Cardiac Arrest (1762); Hemolysis (1886)
|
Event Date 09/21/2022 |
Event Type
Injury
|
Event Description
|
It was reported that at an unknown time during continuous renal replacement therapy with a prismaflex oxiris set and a prismaflex control unit, reddish effluent was observed.No blood leak detection alarm was generated, and no effluent sampling was reported for confirmation of red blood cells.It was further reported the patient experienced hemolysis and cardiac arrest.It was reported the patient received continuous cardiac compression rescue.At the time of this report the patient outcome was not reported.No additional information is available.
|
|
Manufacturer Narrative
|
(b)(6).Oxiris c is similar to oxiris and oxiris s.Oxiris and oxiris s have been temporarily approved for use in the us under emergency use authorization eua200164 with a specific indication to treat patients with covid-19 infection.Should additional relevant information become available, a supplemental report will be submitted.
|
|
Manufacturer Narrative
|
Additional information: h3, h6 and h10.H10: the actual sample was not available; however, photos of the sample were provided for evaluation.Visual inspection observed a red coloration in the effluent fluid.The reported condition was verified.The cause could not be determined.A batch review was conducted and there were no deviations found related to this reported condition during the manufacture of this lot.Should additional relevant information become available, a supplemental report will be submitted.
|
|
Search Alerts/Recalls
|